We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Using Heated Nanoscale Bioprobes to Kill Breast Cancer Cells

By Biotechdaily staff writers
Posted on 22 Mar 2007
Tiny bioprobes have been developed that can be used with molecularly targeted therapeutic heat to kill malignant breast cancer cells--without damaging neighboring healthy tissue. More...


Many researchers have evaluated using heat in treating cancer, but "the inability to deposit effective doses of heat in a tumor without applying similar heat to nearby normal tissue has prevented widespread clinical use,” said Dr. Sally J. DeNardo, professor of internal medicine and radiology with the School of Medicine at the University of California-Davis (UC Davis; Sacramento, USA). "Our animal study, which combined the future-oriented sciences of nanotechnology and molecular imaging, shows that a method for delivering thermal ablation--removing or destroying cancer cells by using heat--is feasible,” added the co-director of the university's radiodiagnosis and therapy section. "This exciting study, combining radiolabeled antibodies with nanoparticles or bioprocess, provides a new approach to direct thermal ablation specifically to tumor cells,” she noted.

Dr. DeNardo stressed that this heat treatment is still in the preclinical, developmental stage, having been used only in laboratory mice; further studies will need to be performed with cancer patients. The study was published in the March 2007 Journal of Nuclear Medicine.

Scientists from UC Davis and Triton Biosystems, Inc. (Chelmsford, MA, USA) injected trillions of magnetic iron-containing bioprobes into the bloodstream of a laboratory mouse bearing a human cancer tumor. The magnetic iron nanoprobes--more than 10,000 of which can fit on the end of a straight pin--are hidden in polymers and sugars, making them virtually invisible to the body's immune system. Antibodies (joined with a radioactive substance) on these probes latched onto receptors that are on the surface of tumor cells. The heating of the probes can be activated and controlled by the use of a magnetic field from outside the body. By applying an alternating magnetic field to the tumor area, the magnetic spheres altered polarity thousands of times per second and created heat. This heat weakened and destroyed the cancer cells. Upon deactivation of the magnetic field, the bioprobes cooled and passed out of the body.

Dr. DeNardo, commented, "By using heat--along with nanoparticles and a radiolabeled antibody--our quantitative imaging directed, and made safer, the application and development of therapy for cancer. This technique could join other cancer therapies, especially for cancers that are hard to treat now, such as breast cancer and metastatic melanoma.”


Related Links:
University of California-Davis
Triton Biosystems

New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Hematology Consumables
Bioblood Devices
New
Automated Urinalysis Solution
UN-9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Plasma pTau217 testing can predict future amyloid accumulation and cognitive decline in cognitively healthy older adults (photo courtesy of Shutterstock)

Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms

Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read more

Industry

view channel
Image: Pathlight combines WGS and dPCR to identify and longitudinally track large‑scale genomic changes, known as structural variants (photo courtesy of SAGA Diagnositcs)

Roche Affiliate Expands MRD Portfolio with SAGA Acquisition

Foundation Medicine, Inc., an independent affiliate of Roche, announced plans to expand its monitoring portfolio with SAGA Diagnostics’ Pathlight, a personalized, tumor-informed molecular residual disease... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.